Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer

We designed a single-arm, open label phase II study to determine the efficacy and toxicity of the combination of pazopanib with CapeOx (capecitabine and oxaliplatin) in metastatic /recurrent advanced gastric cancer (AGC) patients. Previously untreated AGC patients received capecitabine (850 mg/m(2)...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Kim, Seung Tae, Lee, Jeeyun, Lee, Su Jin, Park, Se Hoon, Jung, Sin-Ho, Park, Young Suk, Lim, Ho Yeong, Kang, Won Ki, Park, Joon Oh
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2016
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5029686/
https://ncbi.nlm.nih.gov/pubmed/27003363
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8175
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items